NASDAQ · SKIN

SkinHealth Systems Inc.

$0.75 +$0.02 (+2.16%) 1D Pre-market

Key Metrics

$94.89M
Market cap
P/E · TTM
$296.12M
Revenue · TTM
−$6.05M
Net income
EPS · TTM $-0.05
Dividend yield
Free cash flow $28.45M
Beta · 1Y 1.66
EBITDA · TTM −$993.00K
Gross margin 64.9%

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 20.3 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Jul 7
    The stock moved +47.0% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Jul 7
  • May 8
    From its Jan 30 high, the share price fell 61%.

    Peak close $1.50 on Jan 30; trough close $0.58 on May 8. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -61%
  • May 8
    The stock moved -36.3% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, May 8

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$94.89M
Enterprise value
Shares outstanding129.6M
52-wk range$0.55 – $2.69
Avg volume · 20D1.9M
Net cash
Book value / share$0.44
IndustrySurgical & Medical Instruments & Apparatus
ExchangeNASDAQ
About SkinHealth Systems Inc.
IPO dateMay 6, 2021
Employees613

SkinHealth Systems Inc is a world-wide medical aesthetics company delivering an integrated ecosystem of clinically validated solutions designed to help consumers achieve superior skin health and support the success of providers. Its brands are Hydrafacial and SkinStylus.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S0.32
P/FCF3.34
EV/EBITDA
EV/Sales
Graham №

Profitability

Gross 64.9%
Operating -1.2%
Net -2.0%
FCF 9.6%
ROE / ROIC -11.3% · —

Financial Health

Current ratio1.79
Quick ratio1.48
Debt / equity
Debt / EBITDA
Net cash
Working capital$122.49M

Cash Flow · TTM

Operating CF $28.94M
Capex −$482.00K
Free cash flow $28.45M
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

5 / 9
Middling fundamentals · 5 of 9 signals passing

Altman Z-Score

-0.5
Distress zone (< 1.81) · elevated risk

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings